|
|
Volumn 11, Issue 5, 2012, Pages 419-
|
|
Glybera and the future of gene therapy in the European Union
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIPOGENE TIPARVOVEC;
LIPID;
LIPOPROTEIN LIPASE;
PARVOVIRUS VECTOR;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG INFORMATION;
EUROPEAN UNION;
GENE THERAPY;
HEALTH CARE ORGANIZATION;
HUMAN;
HYPERLIPOPROTEINEMIA TYPE 1;
LETTER;
LIPID BLOOD LEVEL;
MEDICAL DECISION MAKING;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
VIRAL GENE DELIVERY SYSTEM;
X LINKED SEVERE COMBINED IMMUNODEFICIENCY;
ANIMALS;
GENE THERAPY;
HUMANS;
RARE DISEASES;
|
|
EID: 84860373838
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3572-c1 Document Type: Letter |
|
Times cited : (58)
|
|
References (1)
|
